INTRODUCTION {#sec1-1}
============

With advances in pediatric cardiac surgery, surgical repair of Tetralogy of Fallot (TOF) in early infancy has become standard practice in many institutions worldwide. However in a critically ill neonate with severe hypoxia, surgical repair is expected to carry a high morbidity and mortality risk. Generally a modified Blalock Taussig (mBT) shunt is the preferred initial palliation. However, neonatal mBT shunt unlike that performed in older infant is also associated with increased morbidity and mortality. A less invasive alternative is stenting the right ventricular outflow tract (RVOT) or the patent ductus arteriosus (PDA) in the catheterization laboratory. RVOT stenting is technically less demanding compared to PDA stenting and has been shown provide good palliation with low complications. Furthermore, the ductus arteriosus is not always patent beyond the first 2-3 weeks of life.

CASE REPORT {#sec1-2}
===========

A 1-month-old boy was referred to our hospital due to severe and progressively worsening cyanosis and tachypnea. He weighed 3.3 kg. On examination, he was saturating 58% and had severe respiratory distress. The child was intubated and put on ventilator. Echocardiogram showed Tetralogy of Fallot (TOF) with severe infundibular stenosis. Right and left pulmonary arteries were 4.8 mm and 3.3 mm, respectively. Nakata index was 131. Pulmonary artery valve annulus was rather large 5.6 mm (z-score - 2.1), but the infundibular area was 2.2 mm. Patent ductus arteriosus (PDA) was almost closing despite prostaglandin E1 infusion. The patient was brought to the catheterization laboratory as an emergency case for the PDA or right ventricular outflow tract (RVOT) stenting. Descending aortogram was done using 4F pigtail catheter, and PDA anatomy was profiled. The ductus came from underneath transverse aortic arch with tight curve and constricted at the pulmonary artery side \[[Figure 1](#F1){ref-type="fig"}\]. We decided to proceed the RVOT stenting at first. Right ventricular angiogram was done using 5F Judkins right (JR) catheter. Outflow tract was severely thickened with the prominent muscle bundle at end systole, and valve was doming. 5F Launcher guiding JR catheter was positioned at the lower part of outflow tract, and Hi-torque Balance Middleweight Elite guidewire 0.014 inch (Abbott Laboratories, Abbott Park, Illinois, USA) was advanced distally in the right pulmonary artery. After removing 4F Judkins catheter, Accuforce coronary balloon (Terumo Interventional Systems, Somerset, New Jersey, USA) 5 mm × 12 mm was placed across the pulmonary valve and dilated at its maximum pressure. A waist of the balloon was not observed. Oxygen saturation did not improve at all. Then, Azule coronary stent (OrbusNeich, Wanchai, Hong Kong) 3.5 mm × 12 mm was deployed across the RVOT just below the pulmonary valve to open the RVOT and preserve the pulmonary valve at the same time. Nevertheless, the stent migrated downward as the balloon was deflated and wire removed \[[Figure 2](#F2){ref-type="fig"}\]. The child developed complete heart block, and a temporary pacing wire was inserted to the right ventricle and pacing started. We decided to convert to the PDA stenting. Right axillary artery access was taken with 4F sheath. Judkins catheter 4F was positioned at the mouth of duct artery, and hand angiogram of the PDA delineated the anatomy of PDA and arborization branch pulmonary arteries. We decided to balloon dilate the PDA at first. Runthrough guide-wire (Terumo Interventional Systems, Somerset, New Jersey, USA) 0.014 inch was positioned distally in the left pulmonary artery. A 2.5 mm × 15 mm Tazuna percutaneous transluminal coronary angioplasty balloon (Terumo Interventional Systems, Somerset, New Jersey, USA) was set across the PDA and dilated to its maximum caliber. Choice PT Floppy Guide Wire (Boston scientific, Marlborough, Massachusetts, USA) was positioned beside the first wire in the left pulmonary artery as a support. The first Runthrough wire was repositioned in the right pulmonary artery, and Accuforce coronary balloon 3.5 mm × 12 mm was set across the PDA and dilated after removing the second wire. Integrity coronary stent (Medtronic CardioVascular, Santa Rosa, California, USA) 3.5 mm × 18 mm positioning to the PDA followed this. Multiple hand injections at the PDA were done to make sure the stent position, and finally, the stent was deployed. After PDA stenting, oxygen saturation increased from 58% to 84%. The postprocedure descending aortogram revealed good stent position, entirely covering PDA \[[Figure 3](#F3){ref-type="fig"}\]. Postprocedure echocardiography showed the migrated stent hung at the tricuspid valve and ventricular septal defect but did not cause valve insufficiency. Complete atrioventricular block improved 1 day after the procedure, and the temporary pacemaker was discontinued. The child was extubated on the 4^th^ day and transferred to the step-down unit ward on the 6^th^ day. Six months later, the patient was referred to the TOF repair. Computed tomography before surgery showed well-developed pulmonary arteries. Right and left pulmonary artery sizes were 6.4 mm and 5.6 mm, respectively, and Nakata index increased to 200. At the surgery, PDA stent was divided and removed. The migrated stent was located in the trabecular portion below the aortic valve. The stent was retrieved completely. There were no adhesions on its surface. Pulmonary valve and branch pulmonary artery sizes were good. TOF repair was completed without using transannular patch.

![Patent ductus arteriosus angiogram by lateral view. Patent ductus arteriosus was from underneath aortic arch with a tight curve and constricted at distal end](APC-10-206-g001){#F1}

![Left side panels show anterior-posterior view, and right side panels show lateral view. Right ventricular angiogram showed severe infundibular stenosis (a and b). Stent was deployed just below the pulmonary valve (c and d) but migrated downward after balloon deflation (e and f)](APC-10-206-g002){#F2}

![4F Judkins right catheter was inserted through right axillary artery (a). Predilatation of patent ductus arteriosus was done (b). Stent was deployed across patent ductus arteriosus (c). Good flow to branch pulmonary arteries (d)](APC-10-206-g003){#F3}

DISCUSSION {#sec1-3}
==========

Surgical repair of TOF during infancy has become standard practice in many institutions worldwide.\[[@ref1]\] Hence, the need for initial palliation -- usually by Blalock--Taussig (BT) shunt -- has decreased significantly. Palliation is largely reserved for ill neonates with severe hypoxia or those with very small pulmonary arteries as surgical repair in these patients is considered a high-risk procedure RVOT stenting and PDA stenting in those where the ductus is still patent are gaining acceptance as a less invasive alternative compared to palliation with modified BT (mBT) shunt.\[[@ref2]\] Complications related to thoracotomy such as pleural effusion and diaphragm paralysis are avoided.

Technically, RVOT stenting is relatively less challenging compared to PDA stenting. It has also the merit of increasing pulmonary blood flow from the systemic venous blood, hence reducing the LV volume overload that occurs with PDA stenting or BT shunt. At the same, equal distribution of flow to both pulmonary arteries can be expected compared to mBT shunt or PDA stenting as the PDA has a tendency to connect to a branch pulmonary artery (usually left pulmonary artery in the left aortic arch).

Much emphasis in the current surgical literature on the merit of pulmonary valve preservation at the time of surgical repair in TOF to prevent late sequelae of severe pulmonary regurgitation.\[[@ref3]\] The majority of cases subjected to RVOT stenting have small pulmonary valve annulus that will require transannular patch, hence anchoring the stent across the annulus -- which also destroys the valve cusps -- is not an issue.

The RVOT stent was able to be placed as planned. However, as the RVOT is a contractile structure, the stent position was unstable and migrated into the RV body. For a stent to remain stable in such a structure, a considerably larger size would be needed, but we have to pay attention to excessive flow to the lungs and pulmonary edema.
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